KITE-439 Trial: Phase 1 Data for HPV16-Positive Cancer T-Cell Therapy

A clinical trial data sheet describes the KITE-439 Phase 1 trial of HPV16 E7 T-cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers. The document, authored by Kedar Kirtane and shared on figshare under a CC-BY-4.0 license, details patient treatment, safety outcomes, and preliminary efficacy results. It was last updated on 2026-05-21.

Use Cases

• Reviewing safety and tolerability data for a novel T-cell therapy based on the reported dose-limiting toxicities and adverse events.
• Analyzing preliminary efficacy signals based on the reported patient response outcomes (partial response, stable disease).
• Examining manufacturing and cell persistence details based on the described T-cell engineering process and post-infusion detection.
• Benchmarking lymphodepletion and IL-2 support regimens based on the described chemotherapy and cytokine administration protocol.

Strengths

• Provides specific clinical trial details, including dosing (1×10⁶–1×10⁸ cells/kg) and patient count (8 HLA-A*02:01+ patients).
• Reports concrete safety and efficacy endpoints, such as the absence of dose-limiting toxicities and one partial response.
• Includes a detailed description of the T-cell manufacturing process and treatment protocol.

Limitations

• The dataset is a single 399.0 KB DOCX file, indicating a very limited scope and likely a summary document rather than raw patient-level data.
• Row count and column-level documentation are unknown, which limits suitability assessment for quantitative analysis.
• Description metadata is limited; actual data quality and structure require manual inspection after download.

Provenance

Source

Kedar Kirtane via figshare

Collection Method

Clinical trial data collection from the KITE-439 Phase 1 trial.

Freshness

Last updated 2026-05-21 09:39:03; freshness should be verified.